ESMO 2019 — Overview of Presidential Symposium I: ovarian and lung cancer

  • Ben Gallarda
  • Oncology Conference reports
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

The first Presidential Symposium of ESMO 2019 highlighted improved outcomes with PARP inhibition in ovarian cancer, combination immunotherapy in NSCLC, and a third-generation EGFR-TKI in NSCLC.


Niraparib monotherapy in ovarian cancer after first-line chemotherapy:

  • Patients with homologous recombination deficiency (HRD) saw a median PFS of 21.9 vs 10.4 months with placebo (HR 0.43).
  • Similar benefits were seen in HRD patients with and without BRCA mutations (BRCAm).
  • Full coverage on Univadis.

Olaparib plus bevacizumab as maintenance therapy in ovarian cancer:

  • Improvement in median PFS was seen in the overall population (22.1 vs 16.6 months, HR 0.59), and was even greater in BRCAm (HR 0.31) and HRD (HR 0.33) subgroups.
  • PARP inhibition could move beyond BRCA mutations and raises the question of HRD testing in ovarian cancer.
  • Full coverage on Univadis.

Veliparib with front-line chemotherapy and maintenance in high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin:

  • Three-tiered median PFS analysis showed benefit across subgroups: BRCAm 34.7 vs 22.0 months (HR 0.44); HRD 31.9 vs 20.5 (HR 0.57); intent-to-treat 23.5 vs 17.3 months (HR 0.68)
  • Interim analysis of veliparib only during chemotherapy showed similar results as also continuing with maintenance phase.

Adding first-line options in NSCLC – nivolumab+ipilimumab immunotherapy combination:

  • The combination improved OS in patients both positive for PD-L1 (17.1 vs 14.9 months, HR 0.79) and negative (17.2 vs 12.2 months, HR 0.62).
  • The number of first-line treatment options for NSCLC continues to grow.
  • Full coverage on Univadis.

Third-generation TKI as first-line treatment for EGFR-mutated NSCLC:

  • Even with active first generation TKI comparator, osimertinib improved median OS from 31.8 to 38.6 months (HR 0.799).
  • Benefit maintained across subgroups.